In this study, the synthesis, physico-chemical characterization, and antiproliferative effects of a polymer—doxorubicin conjugate targeted by the amide of peptide sequence CPLHQRPMC are described. This sequence is discovered using the phage display method to achieve high affinity to prostate cancer cell line PC3MM2. The peptide is bound to N-(2-hydroxypropyl)methacrylamide-based copolymer carrier via a hydrophilic undeca(ethylene oxide) spacer. Doxorubicin is attached to the polymer using a pH-sensitive hydrazone bond which proves to be stable at a physiological pH 7.4 but quickly hydrolyzes at pH 5.0. The polymer—drug conjugate exhibits significant antiproliferative activity against human metastatic prostate cancer cell line PC3MM2 in vitro. The addition of a second polymer with the targeting peptide but without doxorubicin to the incubation media leads to a decrease in the cytotoxicity of 32% induced by the first polymer. This finding indicates a receptor-specific endocytosis of the polymeric drug.
Kopeček, J., Kopečková , P., Minko, T. and Lu , Z.R. (2000). HPMA Copolymer-anticancer Drug Conjugates: Design, Activity, and Mechanism of Action, Eur. J. Pharm. Biopharm., 50(1): 61—81.
2.
Monfardini, C. and Veronese, F.M. (1998). Stabilization of Substances in Circulation, Bioconjugate Chem., 9(4): 418—450.
3.
Duncan, R. (2006). Polymer Conjugates as Anticancer Nanomedicines , Nat. Rev. Cancer, 6(9): 688—701.
4.
Avichezer, D. , Schechter, B. and Arnon, R. (1998). Functional Polymers in Drug Delivery: Carrier-supported CDDP (cis-platin) Complexes of Polycarboxylates — Effect on Human Ovarian Carcinoma, React. Funct. Polym., 36(1): 59—69.
5.
Šubr, V., Strohalm, J., Hirano, T., Ito, Y. and Ulbrich, K. (1997). Poly [N-(2hydroxypropyl)methacrylamide] Conjugates of Methotrexate — Synthesis and in vitro Drug Release, J. Controlled Release, 49(2—3): 123—132.
6.
Putnam, D. and Kopeček, J. (1995). Enantioselective Release of 5-Fluorouracil from N-(2-Hydroxypropyl)Methacrylamide-Based Copolymers Via Lysosomal-Enzymes, Bioconjugate Chem., 6(4): 483—492.
7.
Maeda, H. and Matsumura, Y. (1989). Tumoritropic and Lymphotropic Principles of Macromolecular Drugs, Crit. Rev. Ther. Drug Carrier Syst., 6(3): 193—210.
8.
Maeda, H., Wu, J., Sawa, T., Matsumura, Y. and Hori, K. (2000). Tumor Vascular Permeability and the EPR Effect in Macromolecular Therapeutics: A Review, J. Controlled Release , 65(1—2): 271—284.
9.
Jaracz, S., Chen, J., Kuznetsova, L.V. and Ojima, L. (2005). Recent Advances in Tumor-targeting Anticancer Drug Conjugates, Bioorgan. Med. Chem., 13(17): 5043—5054.
10.
Chari, R.V.J. , Jackel, K.A., Bourret, L.A., Derr, S.M., Tadayoni, B.M., Mattocks, K.M., Shah, S.A., Liu, C.N., Blattler, W.A. and Goldmacher , V.S. (1995). Enhancement of the Selectivity and Antitumor Efficacy of A Cc-1065 Analog through Immunoconjugate Formation, Cancer Res., 55(18): 4079—4084.
11.
Chari, R.V.J. (1998). Targeted Delivery of Chemotherapeutics: Tumor-activated Prodrug Therapy, Adv. Drug Delivery Rev., 31(1—2): 89—104.
12.
Cohenuram, M. and Saif, M.W. (2007). Panitumumab the First Fully Human Monoclonal Antibody: from the Bench to the Clinic, Anti-cancerDrug, 18(1): 7—15.
13.
Shadidi, M. and Sioud, M. (2003). Selective Targeting of Cancer Cells using Synthetic Peptides, Drug Resist Update , 6(6): 363—371.
14.
Mori, T. (2004). Cancer-specific Ligands Identified from Screening of Peptide-display Libraries, Curr. Pharm. Des., 10(19): 2335—2343.
15.
Alessi, P., Ebbinghaus, C. and Neri, D. (2004). Molecular Targeting of Angiogenesis, BBA-RevCancer, 1654(1): 39—49.
16.
Yamamoto, Y. , Tsutsumi, Y. and Mayumi, T. (2002). Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-soluble Polymeric Modifier for Enhancement of Antimetastatic Effect, Curr. Drug Targets, 3(2): 123—130.
17.
Aina, O.H., Sroka, T.C., Chen, M.L. and Lam, K.S. (2002). Therapeutic Cancer Targeting Peptides, Biopolymers, 66(3): 184—199.
18.
Kaiser, E., Colescot, R.L., Bossinge, C.D. and Cook, P.I. (1970). Kaiser's Test, Anal. Biochem. , 34(2): 595.
19.
Vojkovsky, T. (1995). Chloranile Test, Pept. Res., 8(4): 236.
20.
Guy, C.A. and Fields, G.B. (1997). Trifluoroacetic Acid Cleavage and Deprotection of Resin-bound Peptides Following Synthesis by Fmoc Chemistry, Methods Enzymol., 289(1): 67—83.
21.
Kovář, L., Strohalm, J., Chytil, P., Mrkvan, T., Kovář, M., Hovorka, O., Ulbrich, K. and Říhová , B. (2007). The Same Drug but a Different Mechanism of Action: Comparison of Free Doxorubicin with Two Different N-(2-Hydroxypropyl)methacrylamide Copolymer-Bound Doxorubicin Conjugates in EL-4 Cancer Cell Line, Bioconjugate Chem., 18(3): 894—902.
22.
Ulbrich, K., Šubr, V., Strohalm, J., Plocová, D., Jelínková, M. and Říhová, B. (2000). Polymeric Drugs Based on Conjugates of Synthetic and Natural Macromolecules I. Synthesis and Physico-chemical Characterisation, J. Controlled Release, 64(1—3): 63—79.
23.
Kissel, M., Peschke, P., Šubr, V., Ulbrich, K., Schuhmacher, J., Debus, J. and Friedrich, E. (2001). Synthetic Macromolecular Drug Carriers: Biodistribution of Poly [(N-2-hydroxypropyl)methacrylamide] Copolymers and Their Accumulation in Solid Rat Tumors, PDA J. Pharm. Sci. Technol., 55(3): 191—201.
24.
Mosmann, T. (1983). Rapid Colorimetric Assay for Cellular Growth and Survival — Application to Proliferation and Cyto-Toxicity Assays, J. Immunol. Methods, 65(1—2): 55—63.
25.
Sgouras, D. and Duncan, R. (1990). Methods for the Evaluation of Biocompatibility of Soluble Synthetic-Polymers Which Have Potential for Bio-Medical Use 1. Use of the Tetrazolium-Based Colorimetric Assay (Mtt) As A Preliminary Screen for Evaluation of Invitro Cytotoxicity, J. Mater. Sci.: Mater. Med., 1(2): 61—68.
26.
Etrych, T., Chytil, P., Jelínková, M., Říhová, B. and Ulbrich, K. (2002). Synthesis of HPMA Copolymers Containing Doxorubicin Bound via a Hydrazone Linkage. Effect of Spacer on Drug Release and in vitro Cytotoxicity, Macromol. Biosci., 2(1): 43—52.
27.
Rudolph, J. , Theis, H., Hanke, R., Endermann, R., Johannsen, L. and Geschke, F.U. (2001). Seco-cyclothialidines: New Concise Synthesis, Inhibitory Activity toward Bacterial and Human DNA Topoisomerases, and Antibacterial Properties, J. Med. Chem. , 44(4): 619—626.
28.
Eleftheriou, S., Gatos, D., Panagopoulos, A., Stathopoulos, S. and Barlos, K. (1999). Attachment of Histidine, Histamine and Urocanic Acid to Resins of the Trityl-type, Tetrahedron Lett., 40(14): 2825—2828.
29.
Seymour, L.W. , Duncan, R., Strohalm, J. and Kopeček , J. (1987). Effect of Molecular-Weight (Mbarw) of N-(2-Hydroxypropyl)Methacrylamide Copolymers on Body Distribution and Rate of Excretion After Subcutaneous, Intraperitoneal, and Intravenous Administration to Rats, J. Biomed. Mater. Res., 21(11): 1341—1358.
30.
Kataoka, K., Matsumoto, T., Yokoyama, M., Okano, T., Sakurai, Y., Fukushima, S., Okamoto, K. and Kwon, G.S. (2000). Doxorubicin-loaded Poly(ethylene glycol)-poly(beta-benzyl-l-aspartate) Copolymer Micelles: Their Pharmaceutical Characteristics and Biological Significance , J. Controlled Release, 64(1—3): 143—153.
31.
Hovorka, O., Etrych, T., Šubr, V., Strohalm, J., Ulbrich, K. and Říhová, B. (2006). HPMA Based Macromolecular Therapeutics: Internalization, Intracellular Pathway and Cell Death Depend on the Character of Covalent Bond between the Drug and the Peptidic Spacer and also on Spacer Composition, J. Drug Target, 14(6): 391—403.
32.
Šírová, M., Strohalm, J., Šubr, V., Plocová, D., Rossmann, P., Mrkvan, T., Ulbrich, K. and Říhová , B. (2007). Treatment with HPMA Copolymer-based Doxorubicin Conjugate Containing Human Immunoglobulin Induces Long-lasting Systemic Anti-tumour Immunity in Mice, Cancer Immunol. Immunother1., 56(1): 35—47.
33.
Chytil, P., Etrych, T., Koňák, C., Šírová, M., Mrkvan, T., Říhová, B. and Ulbrich, K. (2006). Properties of HPMA Copolymer-doxorubicin Conjugates with pH-controlled Activation: Effect of Polymer Chain Modification, J. Controlled Release, 115(1): 26—36.
34.
Floyd, J.D. , Nguyen, D.T., Lobins, R.L., Bashir, Q., Doll, D.C. and Perry, M.C. (2005). Cardiotoxicity of Cancer Therapy, J. Clin. Oncol., 23(30): 7685—7696.
